M&A Deal Summary

Pfizer Acquires Biohaven Pharmaceutical Holding

On May 10, 2022, Pfizer acquired life science company Biohaven Pharmaceutical Holding for 11.6B USD

Acquisition Highlights
  • This is Pfizer’s 37th transaction in the Life Science sector.
  • This is Pfizer’s 7th largest (disclosed) transaction.
  • This is Pfizer’s 29th transaction in the United States.
  • This is Pfizer’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2022-05-10
Target Biohaven Pharmaceutical Holding
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 11.6B USD

Target

Biohaven Pharmaceutical Holding

New Haven, Connecticut, United States
Biohaven Pharmaceutical Holding is a biopharmaceutical company engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. Biohaven Pharmaceutical Holding was incorporated in 2013 and is based in New Haven, Connecticut.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 41 of 43
Sector (Life Science) 37 of 39
Type (Add-on Acquisition) 29 of 31
State (Connecticut) 1 of 1
Country (United States) 29 of 31
Year (2022) 2 of 3
Size (of disclosed) 7 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-07 ReViral

Hertfordshire, United Kingdom

ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on treating respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in a global phase 2 pediatric clinical study (REVIRAL1). ReViral was founded in and is based in Hertfordshire, England.

Buy $525M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-08 GBT

San Francisco, California, United States

GBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor.

Buy $5.4B
Mergr

Product

Company

Legal